Non-homologous End Joining Inhibitor SCR-7 to Exacerbate Low-dose Doxorubicin Cytotoxicity in HeLa Cells

Among the genotoxic drug regimens, doxorubicin (DOX) is known for its high-dose side effects in several carcinomas, including cervical cancer. This study reports on testing the combined use of a DOX genotoxic drug and SCR-7 non-homologous end joining (NHEJ) inhibitor for HeLa cells. An in vitro DNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Ajay, Bhatkar, Devyani, Jahagirdar, Devashree, Sharma, Nilesh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Cancer Prevention 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380189/
https://www.ncbi.nlm.nih.gov/pubmed/28382286
http://dx.doi.org/10.15430/JCP.2017.22.1.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380189/
https://www.ncbi.nlm.nih.gov/pubmed/28382286
http://dx.doi.org/10.15430/JCP.2017.22.1.47

Ejemplares similares